samedan logo
 
 
spacer
home > pmps > autumn 2008 > clinical certainty
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Clinical Certainty

Four years after establishing our own clinical manufacturing business, it is more apparent than ever, both to us and to others in the industry, that the sector is in a constant state of development and innovation. New technologies, changing market conditions and an increasingly rigid regulatory regime have all combined to present both challenges and opportunities. No single development or circumstance stands out as the key catalyst for change; there are a whole range of factors that can make the difference between success and failure for an expanding small or medium clinical manufacturing company.

GROWTH

The first issue for any business is the pursuit of growth and how this goal is to be managed and achieved. The market exists, but it is vital that a planned expansion strategy is put into place and then followed. Part of the reason for this is to protect standards, whether stipulated by a regulator or demanded by a client, which must then be met.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
With more than 30 years’ experience in quality assurance, manufacturing and research and development, Brian Dougherty has a breadth of expertise across the pharmaceutical sector. A registered pharmacist, achieving QP status in 1983, he set up SCM Pharma Ltd in 2004 with business partner Fiona Cruickshank. Brian is Chair of the Association of Specials Manufacturers (ACSM), a member of the Chartered Institute of Directors and an elected member of the Industrial Pharmacist Group (of the Royal Pharmaceutical Society).
spacer
Brian Dougherty
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

X-Chem Acquires ComInnex

WALTHAM, Mass.; Oct. 25, 2021 (Business Wire) – X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement